Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQTNASDAQ:JANXNASDAQ:RNACNASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$13.83+0.0%$14.75$6.99▼$17.75$1.65B1.872.37 million shs311,883 shsJANXJanux Therapeutics$23.51-7.2%$29.06$22.52▼$71.71$1.40B3.24858,013 shs239,771 shsRNACCartesian Therapeutics$10.23+0.3%$12.78$8.85▼$41.87$265.34M0.51115,785 shs8,826 shsTARSTarsus Pharmaceuticals$40.92-1.3%$48.21$20.08▼$57.28$1.71B0.94693,158 shs296,596 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics-3.96%-3.49%+9.77%+4.62%+72.97%JANXJanux Therapeutics-2.80%-0.96%-12.05%-31.13%-49.33%RNACCartesian Therapeutics-2.30%-3.50%-4.40%-46.09%-52.45%TARSTarsus Pharmaceuticals-6.20%-10.74%-10.70%-20.77%+8.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQTArcutis Biotherapeutics2.7786 of 5 stars4.41.00.00.03.40.80.6JANXJanux Therapeutics2.326 of 5 stars3.50.00.00.04.13.30.0RNACCartesian Therapeutics1.4881 of 5 stars3.40.00.00.01.63.30.0TARSTarsus Pharmaceuticals3.0568 of 5 stars4.50.00.00.03.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.83Moderate Buy$18.8035.98% UpsideJANXJanux Therapeutics 3.09Buy$95.25305.13% UpsideRNACCartesian Therapeutics 2.75Moderate Buy$42.50315.44% UpsideTARSTarsus Pharmaceuticals 3.00Buy$66.3362.11% UpsideCurrent Analyst Ratings BreakdownLatest RNAC, JANX, TARS, and ARQT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025RNACCartesian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$41.00 ➝ $40.005/5/2025TARSTarsus PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$46.00 ➝ $51.005/2/2025TARSTarsus PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $84.004/9/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/9/2025RNACCartesian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$41.00 ➝ $41.004/9/2025RNACCartesian TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.004/3/2025ARQTArcutis BiotherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/3/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/3/2025ARQTArcutis BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.003/14/2025RNACCartesian TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $40.003/13/2025RNACCartesian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$41.00 ➝ $41.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$212.82M7.74N/AN/A$0.94 per share14.71JANXJanux Therapeutics$10.59M131.38N/AN/A$7.46 per share3.15RNACCartesian Therapeutics$34.17M7.76N/AN/A($82.38) per share-0.12TARSTarsus Pharmaceuticals$233.67M7.36N/AN/A$5.95 per share6.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$262.14M-$1.04N/AN/AN/A-140.97%-119.11%-45.95%N/AJANXJanux Therapeutics-$58.29M-$1.36N/AN/AN/A-463.91%-10.47%-9.86%N/ARNACCartesian Therapeutics-$219.71M-$52.83N/AN/AN/A-510.72%N/A-6.03%N/ATARSTarsus Pharmaceuticals-$135.89M-$2.73N/AN/AN/A-103.64%-55.86%-39.28%5/14/2025 (Estimated)Latest RNAC, JANX, TARS, and ARQT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025TARSTarsus Pharmaceuticals-$0.75N/AN/AN/A$71.19 millionN/A5/8/2025Q1 2025JANXJanux Therapeutics-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A5/8/2025Q1 2025RNACCartesian Therapeutics-$0.61-$0.68-$0.07-$0.68$0.69 million$1.10 million5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 million5/1/2025Q1 2025TARSTarsus Pharmaceuticals-$0.69-$0.64+$0.05-$0.64$72.50 million$78.34 million2/27/2025Q4 2024JANXJanux Therapeutics-$0.49-$0.36+$0.13-$0.36N/AN/A2/25/2025Q4 2024ARQTArcutis Biotherapeutics-$0.28-$0.09+$0.19-$0.09$60.52 million$71.36 million2/25/2025Q4 2024TARSTarsus Pharmaceuticals-$0.68-$0.60+$0.08-$0.60$58.80 million$66.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.672.462.38JANXJanux TherapeuticsN/A38.8038.80RNACCartesian TherapeuticsN/A10.7010.70TARSTarsus Pharmaceuticals0.305.425.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/AJANXJanux Therapeutics75.39%RNACCartesian Therapeutics86.95%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.50%JANXJanux Therapeutics8.10%RNACCartesian Therapeutics57.90%TARSTarsus Pharmaceuticals8.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.20 million105.93 millionOptionableJANXJanux Therapeutics3059.17 million37.05 millionOptionableRNACCartesian Therapeutics6425.94 million10.70 millionOptionableTARSTarsus Pharmaceuticals5042.01 million35.07 millionOptionableRNAC, JANX, TARS, and ARQT HeadlinesRecent News About These CompaniesIntegral Health Asset Management LLC Has $19.38 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 14 at 6:17 AM | marketbeat.comD. E. Shaw & Co. Inc. Grows Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 14 at 5:05 AM | marketbeat.comEnsign Peak Advisors Inc Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 13 at 6:32 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Schonfeld Strategic Advisors LLCMay 13 at 4:17 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by The Manufacturers Life Insurance CompanyMay 13 at 4:16 AM | marketbeat.comTarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay OffMay 12 at 12:28 PM | seekingalpha.comTudor Investment Corp ET AL Takes $769,000 Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 10, 2025 | marketbeat.comDimensional Fund Advisors LP Sells 62,658 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 10, 2025 | marketbeat.comTarsus Pharmaceuticals (TARS) to Release Quarterly Earnings on WednesdayMay 9, 2025 | marketbeat.comCaxton Associates LP Buys New Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 9, 2025 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesMay 8, 2025 | globenewswire.comCutter Capital Management LP Invests $6.23 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 8, 2025 | marketbeat.comThe Goldman Sachs Group Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $51.00May 7, 2025 | marketbeat.comVoya Investment Management LLC Purchases 18,000 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 7, 2025 | marketbeat.comRaymond James Financial Inc. Acquires Shares of 19,999 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 7, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $51.00 at The Goldman Sachs GroupMay 7, 2025 | americanbankingnews.comFreestone Grove Partners LP Makes New $439,000 Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 6, 2025 | marketbeat.com6 Analysts Assess Tarsus Pharmaceuticals: What You Need To KnowMay 5, 2025 | benzinga.comTarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to AnalystsMay 5, 2025 | insidermonkey.comUncovering Potential: Supernus Pharmaceuticals's Earnings PreviewMay 5, 2025 | benzinga.comElanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt PaydownMay 5, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNAC, JANX, TARS, and ARQT Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$13.83 +0.01 (+0.04%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Janux Therapeutics NASDAQ:JANX$23.51 -1.82 (-7.18%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Cartesian Therapeutics NASDAQ:RNAC$10.23 +0.03 (+0.29%) As of 10:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.Tarsus Pharmaceuticals NASDAQ:TARS$40.92 -0.54 (-1.30%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oklo Reaches Critical Mass, Atomic Upside Still Available U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer NVIDIA Stock Surges on Bullish News: How High Could It Climb? ON Holding Surges, Leads High-End Retailers Into Reversal D-Wave Pushes Back on Short Seller Case With Strong Earnings NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
